永泰生物(06978.HK)CEO辭任 指控有董事失責卻干預營運
永泰生物-B(06978.HK)公布,王歈已提呈辭任集團執行董事兼首席執行官及首席科技官職務,自2025年6月25日起生效。同時,集團公布即日起,授權集團高級副總裁張鍵代行首席執行官職務,負責公司的日常事務及擔任集團子公司的法人代表。
集團指,王歈辭任是因為與董事會有分歧,王歈指控董事會於2025年4月28日審議通過的內控管理權限規定,嚴重違反他與公司簽訂的勞務合同中關於首席執行官經營管理權限的明確約定,導致勞務合同實質性失效。他表示某董事長期旅居海外,無法有效履責卻干預公司營運;某兩位董事因股東易主已不能代表公司任何股東利益,但仍佔據董事會席位,此舉已嚴重違反公司治理準則;及董事會治理失能與公司願景背離。
集團回應指,董事已考慮上述由王歈提出之觀察及指稱,並認為上述指控毫無根據,因此斷言否定有關指控。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.